Roche has secured a positive opinion from the EU's Committee for Medicinal Products for Human Use ( CHMP) for its oncology candidate Kadcyla, an antibody-drug conjugate which is a follow-up to the breast cancer blockbuster Herceptin.
Roche has secured a positive opinion from the EU's Committee for Medicinal Products for Human Use ( CHMP) for its oncology candidate Kadcyla, an antibody-drug conjugate which is a follow-up to the breast cancer blockbuster Herceptin.
The CHMP recommended approval of Kadcyla (trastuzumab emtansine or T-DM1) as a single agent for the treatment of adult patients...
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
